Metformin
Preeclampsia
University of OuluSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Preeclampsia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aspirin FANG HE | Phase 4 | BBB |
Furosemide University of California, Irvine | Phase 4 | BB |
Atenolol University of Tennessee Graduate School of Medicine | Early Phase 1 | C |
Nifedipine University of Tennessee Graduate School of Medicine | Early Phase 1 | C |
Labetalol University of Tennessee Graduate School of Medicine | Early Phase 1 | C |
Nimodipine FDA Office of Orphan Products Development | N/A | D |
Ferumoxytol University of Wisconsin, Madison | Unknown | D |
2-(Furan-2-ylmethylamino)-5-sulfamoylbenzoic acid University of California, Irvine | Phase 4 | NR |
Same molecule, other indications
Metformin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →